Table 1.
Characteristics of Selected Top Product Families by Medicaid Expenditures on Line Extensions
| Brand name | Generic name | Line extensions | ||
|---|---|---|---|---|
| Type(s) | 2018 spend ($M)* | |||
| Invega/Invega Sustenna | Paliperidone | 10 | Non-oral formulations, modified-release form | 1059.8 |
| Suboxone/Suboxone Film | Buprenorphine/naloxone | 8 | Other oral formulations | 759.7 |
| Latuda | Lurasidone | 5 | Other oral formulations | 586.6 |
| Abilify/Abilify Maintena | Aripiprazole | 19 | Non-oral formulations, other oral formulations | 519.5 |
| Vyvanse | Lisdexamfetamine | 10 | Other oral formulations | 478.6 |
| Onfi | Clobazam | 3 | Other oral formulations | 379.1 |
| Ritalin | Methylphenidate | 16 | Modified-release forms | 348.3 |
| Prezista | Darunavir | 6 | Other oral formulations | 320.9 |
| Xarelto | Rivaroxaban | 12 | Other oral formulations | 264.2 |
| Xifaxan | Rifaximin | 3 | Other oral formulations | 203.7 |
Notes: NDC national drug code. *2018 gross Medicaid expenditures in millions of US dollars